Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daily Lung Function with Albuterol/Salbutamol and Ipratropium in COPD
2012-000384-24Phase 4Completed
- Sponsor
- GSK
- Start
- Apr 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of salbutamol and ipratropium bromide in chronic obstructive pulmonary disease (COPD), sponsored by GSK. Primary endpoint: Variability in daily FEV1. Started Apr 2012; status: completed.
02
Drugs
salbutamolipratropium bromide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2012-000384-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000384-24.